Recent Press Releases

Health Care Providers and Services Stocks under Review - Community Health Systems, Tenet Healthcare, UnitedHealth, Molina Healthcare, and Cigna

Editor Note: For more information about this release, please scroll to bottom.

LONDON, October 6, 2014

Sucampo Announces Departure of Chief Financial Officer

Sucampo Announces Departure of Chief Financial Officer BETHESDA, Md., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today...

Teva Announces Results of Strategic Review of Core Specialty Therapeutic Areas

- Affirms its long-term commitment to being a world-leader in Central Nervous System and Respiratory - - Maintains its current commercial presence but stops Research & Development in other...

Actavis to Acquire Durata Therapeutics, Inc.

Actavis to Acquire Durata Therapeutics, Inc. Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings Enhances Actavis' Long-term Growth Profile...

Information on suspected side effects of nationally authorised medicines now available through a single website

Information on suspected side effects of nationally authorised medicines now available through a single website EMA encourages patients to report suspected side effects As of today, European citizens...

Merck Announces Proposed Public Debt Offering

Merck Announces Proposed Public Debt Offering WHITEHOUSE STATION, N.J., Oct 06, 2014 (BUSINESS WIRE) -- Merck & Co., Inc. (the "Company") MRK, +1.78% known as MSD outside the United States and...

Mylan Launches Generic Combivir(R)

Mylan Launches Generic Combivir(R) Product strengthens growing antiretroviral franchise in the U.S. PITTSBURGH, Oct. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch...

GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director

GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective...

LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages 12-17

LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients...

Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement

RALEIGH, N.C. & LAINATE, Italy, Oct 03, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. ("Salix") SLXP, +5.37% and Cosmo Pharmaceuticals S.p.A. ("Cosmo") (six:COPN) today...

Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range

Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range Third Quarter 2014 Financial Results Conference Call to be Held on Oct. 30, 2014 PITTSBURGH, Oct. 3, 2014...

US HER2-Positive Breast Cancer Treatment Market to More than Treble in Value by 2023, says GlobalData

US HER2-Positive Breast Cancer Treatment Market to More than Treble in Value by 2023, says GlobalData LONDON, UK (GlobalData), 2 October 2014 - The US treatment market for human epidermal growth...

Distribution changes on cancer drugs

Beginning October 1, 2014, Avastin® (bevacizumab), Herceptin® (trastuzumab) and Rituxan® (rituximab) will only be available to hospitals and clinics through authorized specialty...

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® Data from 25 accepted abstracts include...

Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review

Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review SAN DIEGO, Oct 01, 2014 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. ZGNX, +1.74% a...

Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion

Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion Worldwide Collaboration to Market and Develop Portfolio of Soluble Guanylate Cyclase (sGC) Modulators Commences Wednesday,...

The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia